News Scan for Mar 14, 2018

Lassa fever in Nigeria
;
No suicide-Tamiflu link found
;
Chikungunya vaccine trial

Nigeria's Lassa fever total grows, expands to another state

The number of suspected cases in Nigeria's Lassa fever outbreak has climbed to 1,386 over the past week, which includes 12 more confirmed cases and 4 more deaths, the country's Centre for Disease Control (NCDC) said in its latest report for the week ending Mar 11. So far 365 confirmed cases and 114 deaths have been reported.

Since the NCDC's last report, the first confirmed case has been reported in Kaduna state, raising the number of affected states to 19. However, 84% of all the infections are reported from just 3 states: Edo, Ondo, and Ebonyi. Thirty-six people are still being treated for their illnesses, and 1,150 contacts are under monitoring.

The NCDC said it has deployed teams to four states that border Benin as part of enhanced surveillance for the disease.

Lassa fever is primarily spread by rodents, but human transmission can occur by contact with an infected patient's body fluids. So far 16 healthcare workers have been sickened in the outbreak, 4 of them fatally.

In other Lassa developments, the NCDC said in a Mar 12 statement that early results of virus sequencing on the samples from seven lab-confirmed patients, compared with sequences from samples obtained in past years from different part of the country, suggest that no new virus lineages have appeared, that circulating viruses are similar to those from other years, and that the latest cases aren't epidemiologically linked.

"The most likely route of transmission continues to be spillover of viruses from the rodent reservoir to humans rather than extensive human-to-human transmission," the report said.
Mar 13 NCDC situation update
Mar 12 NCDC statement on early sequencing results

 

Study finds no link between increased teen suicide risk and Tamiflu

A large study based on a national claims database found no link between oseltamivir (Tamiflu), the most commonly used drug to treat flu, and an increase risk of suicide in children. A team from the University of Illinois at Chicago published its findings yesterday in Annals of Family Medicine.

In 2006, health officials in Japan raised concerns about psychiatric symptoms in teens who were treated with the drug, which prompted Tamiflu's maker to add a warning to its labeling about the potential for neuropsychiatric effects, such as hallucinations, delirium, self-harm, and suicide. However, clinical studies looking at the association have been inconclusive and fraught with methodology and confounding factors.

James Antoon, MD, PhD, the study's corresponding author and assistant professor of clinical pediatrics at the University of Illinois at Chicago College of Medicine, said in a press release from the school that the link between a drug and suicide is a difficult topic to study. "Many events, which can happen simultaneously or over time, can influence a person to attempt suicide, as can an illness itself—so it can be difficult to study scientifically," he said.

To help tease out the factors, the group used a novel method called a case-crossover design, Antoon said. "This analysis is different because it allowed us to use each individual subject as his or her own comparison—we retrospectively studied how patients behaved when on Tamiflu and compared it to their behavior when they were not taking the drug."

From the claims database, researchers identified 21,047 children ages 1 to 18 who attempted suicide during five recent flu seasons (from 2009 to 2013). Of the group, 251 children were exposed to Tamiflu, based on outpatient pharmacy dispensing data. The mean age was 15 years, 61% were female, and 65% had an underlying mental health diagnosis.

For each patient, the researchers assigned the 10-day period just before the suicide attempt as the case period and identified four earlier control periods during the same flu season, which Antoon said helped the group control for within-person confounders, such depression, mental health, trauma, or abuse. Then they repeated the analysis with flu diagnosis alone, without the use of Tamiflu, to explore if infection itself could have been a confounding factor associated with suicide risk.

The group found no association between exposure to Tamiflu and suicide in the pediatric patients. Antoon said the findings will help alleviate some healthcare provider fears, but they will probably continue prescribing the drug with caution, because there are still questions about other neuropsychiatric side effects, which he said his group will look at in future studies.
Mar/Apr Ann Fam Med study
Mar 13 University of Illinois news release

 

Valneva launches phase 1 trial of chikungunya vaccine

Valneva SE, a vaccine company based in France, announced yesterday the launch of a phase 1 trial to assess the safety and immunogenicity of VLA1553, its live attenuated vaccine against chikungunya.

The multicenter trial will take place in the United States and will evaluate three different dose levels in about 120 healthy adults who will receive one dose, the company said in a press release. To test antibody persistence, investigators will revaccinate participants at 6 and 12 months to assess if they are protected from vaccine-induced viremia.

First data are expected in early 2019, the company said. In preclinical studies in monkeys, VLA1553 prompted strong long-lasting neutralizing antibody response comparable to wild-type chikungunya infection.
Mar 13 Valneva press release

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»